PharmAI
Dresden, Germany
The technology behind PharmAI’s DiscoveryEngine allows for an unprecedented level of detail in the representation of drug-target complexes. Besides geometric comparison of binding sites based on local alignments, non-covalent interactions were included as they significantly improve the prediction of binding site similarities. Over many years, PharmAI refined and improved this technology and applied it to reposition known drugs to new targets for cancer or malaria. At its core, pharmAI’s technology leverages 3D structure of drug-target complex, calculates similarities to produce predictions, and ranks them using artificial intelligence.
Company Info
- Founded
- 2019
- Website
- www.pharm.ai/
Categories
Disease Areas
Technologies
Only accessible to MedStartr community members.
Join nowWhat do you think of PharmAI?
A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.